about
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-ThromPosttraumatic stress, nonadherence, and adverse outcome in survivors of a myocardial infarctionSymptoms of posttraumatic stress disorder in patients who have had a myocardial infarctionThe PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairmentPermutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHFEvaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method.Delayed thrombocytopenia following abciximab therapy.Relaxin: review of biology and potential role in treating heart failure.Comparison and evaluation of antimicrobial susceptibility testing of enterococci performed in accordance with six national committee standardized disk diffusion proceduresDyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.Recent developments in cardiac output determination by bioimpedance: comparison with invasive cardiac output and potential cardiovascular applications.Radiation oncology practice accreditation.The role of the kidney in heart failure.Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.Role of cardiac power in heart failure.Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF.Management of cardiac arrest in 2005: an update.Posttraumatic stress disorder: a missed link between psychiatric and cardiovascular morbidity?Adjunctive pharmacotherapy for coronary interventions-time to read the writing on the wall.The pathophysiology of acute heart failure--is it all about fluid accumulation?Hemodynamic monitoring in acute heart failure.Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation.Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHFVasodilators in the treatment of acute heart failure: what we know, what we don't.Relaxin, a pleiotropic vasodilator for the treatment of heart failure.A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity iThe management of acute heart failure.Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward.Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trialAcute heart failure clinical drug development: from planning to proof of activity to phase III.Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome.Clinical use of novel biomarkers in heart failure: towards personalized medicine.Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond.Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure).A randomized controlled trial of the safety and promise of cognitive-behavioral therapy using imaginal exposure in patients with posttraumatic stress disorder resulting from cardiovascular illness.Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure.Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure.Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
P50
Q28195611-BD93BF80-D579-4639-9936-740E2A30F154Q28209461-2C2981D4-99F3-4E05-AD6D-5BA4BCC55C30Q28217780-5E4B53D0-EE7B-4938-9FA6-B8CF83E024A9Q28297684-E809168C-D243-41BE-BDD5-92E01368A894Q28740781-D51B9DED-4A70-47D6-B68F-1A31E03DE174Q30573371-3494398E-E90F-4AAD-8AC1-D0D301F4005DQ33342589-8EDE11CD-EB3A-4005-BFFE-FB2DD2D30EF7Q33873275-AD17029A-55B2-443E-B87A-EE8B02194790Q33973779-359770C5-B1E1-4FA9-BCBC-BE4A049A7B51Q34148325-0B54D490-0ADA-4449-958B-1C374D6008D4Q34310960-80D764C7-EDCD-445D-954B-E1EDAC7D4EC4Q34314965-1F755075-5F84-4C98-A8E0-4A45CA8616BDQ34582903-75E44C28-455C-4922-B1F4-B3F1C3AD6120Q34641418-C07D845F-AAC3-4A79-86EF-9546A50E9026Q34646866-B7633DE0-3714-4E7B-B348-8C77627A718CQ35162743-9ABA3329-D4E9-415B-9BDA-6C6E8BEF2FAEQ35810391-6BB8F051-4051-4F39-A1C7-1870B60649D4Q36270934-A4ECBE6D-5D70-42CC-97C3-EFA4E87B9F96Q36415279-6382AACC-8C05-4EBD-9468-1D95DC96CAF8Q36680683-DD2C1553-78E4-4B54-8503-DFDBEA8A8CF8Q37033048-50F1FDBD-E2B7-495F-BB17-6F24CB4C2400Q37044877-2FFD81EA-9AB2-4745-8A7C-3816C2B1DD57Q37086300-3066875A-029E-4EC6-8ACD-AE26D23286B3Q37240303-EA2A09E2-BAA8-40F7-89B7-C8A76C78101DQ37355110-3E4A6439-B6D5-4A85-96CB-E30355AE499FQ37356318-B9A07A32-FFD2-463B-AF30-EACB5E609B88Q37583316-0B405652-A90C-4E66-9A57-88BA0FC7BA67Q37653092-2EAEAAD8-D474-4FFC-B536-1B90F45BC919Q37709130-73E46218-3205-4CD1-BFD2-1752D83F843EQ37710255-AAD147C2-4CBE-445F-AACB-545038E87960Q37711521-DD524A2C-65DC-42FD-9810-98C021A58B2CQ37794561-EA2B11A4-F556-457F-927C-4D58C4CB030EQ37891878-28431BAF-A48E-40C5-80C8-97B06C0AC6ABQ38109588-2E136B77-C42C-45A1-A151-AE2E9438B733Q38173317-EBFF33A1-2C12-4371-A81A-92629F766A35Q38343702-CE0D93A7-7ADD-411B-8F1D-3CD7BF8D3FBAQ38373799-10F32234-7B4F-403F-B3AC-3AB6BF7A3FA1Q38387228-7AB5309C-8D88-4E8F-BC04-A2DE38CC208BQ38389044-7215599D-39ED-436E-BC52-5CA342E4A590Q38391668-F1401040-0AC0-41E6-9C24-438243E07EF9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gad Cotter
@ast
Gad Cotter
@en
Gad Cotter
@es
Gad Cotter
@nl
Gad Cotter
@pt
Gad Cotter
@sl
type
label
Gad Cotter
@ast
Gad Cotter
@en
Gad Cotter
@es
Gad Cotter
@nl
Gad Cotter
@pt
Gad Cotter
@sl
prefLabel
Gad Cotter
@ast
Gad Cotter
@en
Gad Cotter
@es
Gad Cotter
@nl
Gad Cotter
@pt
Gad Cotter
@sl
P106
P21
P31
P496
0000-0002-9613-3339
P569
2000-01-01T00:00:00Z